Study identification

EU PAS number

EUPAS103493

Study ID

105087

Official title and acronym

Weight regain after completion of SURMOUNT-CN trial: The SURMOUNT-CN trial follow-up study (SURMOUNT-CN follow-up study)

DARWIN EU® study

No

Study countries

China

Study description

This is a real-world observational study with primary data collection and secondary data use. This follow-up study will enroll patients who completed the SURMOUNT-CN trial, with a planned follow-up duration of 26 weeks. The aim of this follow-up study is to examine changes in body weight and waist circumferences in 26 weeks at 13-weekly intervals from treatment cessation among those who completed SURMOUNT-CN trial in real-world practice settings in China. No investigational medicine is applied in this follow-up study. The follow-up data will be provided by patients, whereas study baseline data (at trial randomization, week 52 and week 56) will be derived from SURMOUNT-CN trial via patient-level data linkage.

Study status

Ongoing
Research institutions and networks

Institutions

Contact details

Lilly China Value Evidence and Outcomes ssi@lilly.com

Study contact

Lilly China Value Evidence and Outcomes

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and company
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable